Dropouts due to adverse events · adults (aged 18‐85)
Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
Comparison 4: NaSSAs may leads to lower treatment efficacy ‐ Treatment response, as measured by the Global… compared with placebo (low certainty).
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18‐85)
Comparison 4: NaSSAs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Major bleedinga · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin leads to higher major bleedinga compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower all cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Emotionalism (primary outcome) · emotionalism after stroke
It is very uncertain whether pharmaceutical interventions changes emotionalism (primary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Emotionalism: mean scores at end of treatment ‐ Pathological Laughter and Crying Scale · emotionalism after stroke
1 finding from 1 review
Depression: Mean scores at end of treatment · emotionalism after stroke
1 finding from 1 review
Cognitive function · emotionalism after stroke
1 finding from 1 review
Activities of daily living · emotionalism after stroke
1 finding from 1 review
Adverse events: 1. death: at end of treatment · emotionalism after stroke
Pharmaceutical interventions showed no clear difference in adverse events: 1. death: at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo or active control (very low certainty).
1 finding from 1 review
Improvement in central macular thickness on OCT · participants with chronic CME (≥ 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved contrast sensitivity · participants with chronic CME (≥ 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · participants with chronic CME (≥ 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistence of visual improvement one month after discontinuation of treatment · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found